Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mast Cells, Mastocytosis, and Related Disorders
Theoharis C. Theoharides, Peter Valent, Cem Akin
New England Journal of Medicine (2015) Vol. 373, Iss. 2, pp. 163-172
Closed Access | Times Cited: 454

Showing 1-25 of 454 citing articles:

Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Peter Valent, Cem Akin, Dean D. Metcalfe
Blood (2016) Vol. 129, Iss. 11, pp. 1420-1427
Open Access | Times Cited: 614
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology
Karin Hartmann, Luís Escribano, Clive Grattan, et al.
Journal of Allergy and Clinical Immunology (2015) Vol. 137, Iss. 1, pp. 35-45
Open Access | Times Cited: 334
Interactions between mesenchymal stem cells and the immune system
Na Li, Jinlian Hua
Cellular and Molecular Life Sciences (2017) Vol. 74, Iss. 13, pp. 2345-2360
Open Access | Times Cited: 300
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future
Peter Valent, Cem Akin, Karin Hartmann, et al.
Cancer Research (2017) Vol. 77, Iss. 6, pp. 1261-1270
Open Access | Times Cited: 231
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Peter Valent, Cem Akin, Karin Hartmann, et al.
HemaSphere (2021) Vol. 5, Iss. 11, pp. e646-e646
Open Access | Times Cited: 204
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
Mohamad Jawhar, Juliana Schwaab, Susanne Schnittger, et al.
Leukemia (2015) Vol. 30, Iss. 1, pp. 136-143
Closed Access | Times Cited: 201
Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders
Theoharis C. Theoharides, Irene Tsilioni, Arti Patel, et al.
Translational Psychiatry (2016) Vol. 6, Iss. 6, pp. e844-e844
Open Access | Times Cited: 197
Long‐COVID syndrome‐associated brain fog and chemofog: Luteolin to the rescue
Theoharis C. Theoharides, Christos Cholevas, Konstantinos S. Polyzoidis, et al.
BioFactors (2021) Vol. 47, Iss. 2, pp. 232-241
Open Access | Times Cited: 187
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Peter Valent, Cem Akin, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology In Practice (2019) Vol. 7, Iss. 4, pp. 1125-1133.e1
Open Access | Times Cited: 185
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
Peter Valent, Cem Akin, Karin Hartmann, et al.
Theranostics (2020) Vol. 10, Iss. 23, pp. 10743-10768
Open Access | Times Cited: 142
Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?
Theoharis C. Theoharides
Molecular Neurobiology (2022) Vol. 59, Iss. 3, pp. 1850-1861
Open Access | Times Cited: 127
Anaphylaxis: A 2023 practice parameter update
David B.K. Golden, Julie Wang, Susan Waserman, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 2, pp. 124-176
Open Access | Times Cited: 87
Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID
Theoharis C. Theoharides, Duraisamy Kempuraj
Cells (2023) Vol. 12, Iss. 5, pp. 688-688
Open Access | Times Cited: 52
Elucidating the role of tumor-associated ALOX5+ mast cells with transformative function in cervical cancer progression via single-cell RNA sequencing
Fu Zhao, Junjie Hong, Guangyao Zhou, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 21
Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6
Irene Tsilioni, Anilia Taliou, Konstantinos Francis, et al.
Translational Psychiatry (2015) Vol. 5, Iss. 9, pp. e647-e647
Open Access | Times Cited: 174
Mast cell activation syndromes
Cem Akin
Journal of Allergy and Clinical Immunology (2017) Vol. 140, Iss. 2, pp. 349-355
Closed Access | Times Cited: 159
Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin
Theoharis C. Theoharides
Frontiers in Neuroscience (2015) Vol. 9
Open Access | Times Cited: 140
Hereditary Alpha Tryptasemia
Jonathan J. Lyons
Immunology and Allergy Clinics of North America (2018) Vol. 38, Iss. 3, pp. 483-495
Open Access | Times Cited: 135
Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
Georg Greiner, Bettina Sprinzl, Aleksandra Górska, et al.
Blood (2020) Vol. 137, Iss. 2, pp. 238-247
Open Access | Times Cited: 135
COVID‐19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin
Theoharis C. Theoharides
BioFactors (2020) Vol. 46, Iss. 3, pp. 306-308
Open Access | Times Cited: 131
SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors
Alexandra Taracanova, Mihail Alevizos, Anna Karagkouni, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 20
Open Access | Times Cited: 121
Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome
Theoharis C. Theoharides, Irene Tsilioni, Mona Abubakr Bawazeer
Frontiers in Cellular Neuroscience (2019) Vol. 13
Open Access | Times Cited: 121
Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism
Arti Patel, Irene Tsilioni, Susan E. Leeman, et al.
Proceedings of the National Academy of Sciences (2016) Vol. 113, Iss. 45
Open Access | Times Cited: 113
New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis
Andreas Reiter, Tracy I. George, Jason Gotlib
Blood (2020) Vol. 135, Iss. 16, pp. 1365-1376
Open Access | Times Cited: 112
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome
Peter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
International Archives of Allergy and Immunology (2019) Vol. 180, Iss. 1, pp. 44-51
Open Access | Times Cited: 111
Page 1 - Next Page

Scroll to top